X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA LUPIN LTD ELDER PHARMA/
LUPIN LTD
 
P/E (TTM) x -0.2 16.5 - View Chart
P/BV x 0.1 3.8 2.6% View Chart
Dividend Yield % 0.0 0.8 -  

Financials

 ELDER PHARMA   LUPIN LTD
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
LUPIN LTD
Mar-16
ELDER PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs3802,127 17.9%   
Low Rs1881,294 14.5%   
Sales per share (Unadj.) Rs491.2304.1 161.5%  
Earnings per share (Unadj.) Rs-3.250.4 -6.3%  
Cash flow per share (Unadj.) Rs14.460.7 23.7%  
Dividends per share (Unadj.) Rs07.50 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs376.5243.8 154.4%  
Shares outstanding (eoy) m20.54450.58 4.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.65.6 10.3%   
Avg P/E ratio x-89.333.9 -263.0%  
P/CF ratio (eoy) x19.728.2 69.9%  
Price / Book Value ratio x0.87.0 10.8%  
Dividend payout %014.9 0.0%   
Avg Mkt Cap Rs m5,833770,740 0.8%   
No. of employees `000NA16.4 0.0%   
Total wages/salary Rs m2,17921,077 10.3%   
Avg. sales/employee Rs ThNM8,379.6-  
Avg. wages/employee Rs ThNM1,289.0-  
Avg. net profit/employee Rs ThNM1,388.7-  
INCOME DATA
Net Sales Rs m10,089137,016 7.4%  
Other income Rs m2571,877 13.7%   
Total revenues Rs m10,346138,893 7.4%   
Gross profit Rs m-79237,535 -2.1%  
Depreciation Rs m3614,635 7.8%   
Interest Rs m2,756446 617.7%   
Profit before tax Rs m-3,65334,330 -10.6%   
Minority Interest Rs m0-88 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m12511,536 1.1%   
Profit after tax Rs m-6522,707 -0.3%  
Gross profit margin %-7.827.4 -28.7%  
Effective tax rate %-3.433.6 -10.2%   
Net profit margin %-0.616.6 -3.9%  
BALANCE SHEET DATA
Current assets Rs m9,24097,790 9.4%   
Current liabilities Rs m9,99853,872 18.6%   
Net working cap to sales %-7.532.1 -23.4%  
Current ratio x0.91.8 50.9%  
Inventory Days Days4685 54.7%  
Debtors Days Days60121 49.5%  
Net fixed assets Rs m10,12486,379 11.7%   
Share capital Rs m206901 22.8%   
"Free" reserves Rs m5,582105,735 5.3%   
Net worth Rs m7,734109,844 7.0%   
Long term debt Rs m4,88953,739 9.1%   
Total assets Rs m22,882224,378 10.2%  
Interest coverage x-0.377.9 -0.4%   
Debt to equity ratio x0.60.5 129.2%  
Sales to assets ratio x0.40.6 72.2%   
Return on assets %11.810.3 114.0%  
Return on equity %-0.820.7 -4.1%  
Return on capital %22.321.2 105.2%  
Exports to sales %3.049.1 6.2%   
Imports to sales %0.47.4 5.7%   
Exports (fob) Rs m30767,244 0.5%   
Imports (cif) Rs m4310,199 0.4%   
Fx inflow Rs m30771,405 0.4%   
Fx outflow Rs m12517,807 0.7%   
Net fx Rs m18153,598 0.3%   
CASH FLOW
From Operations Rs m11,754-3,690 -318.6%  
From Investments Rs m-561-69,434 0.8%  
From Financial Activity Rs m-6,76258,126 -11.6%  
Net Cashflow Rs m4,432-14,998 -29.5%  

Share Holding

Indian Promoters % 39.6 46.6 85.0%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 7.5 11.3 66.4%  
FIIs % 16.8 31.9 52.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 10.1 357.4%  
Shareholders   16,479 98,259 16.8%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   SANOFI INDIA  ASTRAZENECA PHARMA  STRIDES SHASUN LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  

Compare ELDER PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Red; Infosys Tanks as CEO Vishal Sikka Resigns(09:30 am)

Asian indices are lower today as Chinese and Hong Kong shares fall. The Shanghai Composite is off 0.2%, while the Hang Seng is down 0.7%. The Nikkei 225 is trading lower by 0.9%.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE ELDER PHARMA WITH

MARKET STATS